Loading
Amgen Inc Stock: price and insider trades · United States
Amgen Inc: what insiders have been doing
Every trade that managers of Amgen Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Thousand Oaks, United States. It was founded in 1980. 25 insiders have disclosed 85 filings since 18 October 2025.
The flow runs one way only: 10 sales worth €6.5M, from 5 insiders, and no purchase. Gordon Murdo filed the largest sale, €2.0M, on 13 November 2025.
With 85 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Since 2016, the database holds no purchases and 27 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 36.75 bn USD and net income at 7.71 bn USD; the dividend was 9.66 USD per share.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
483
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€22M
27 ops. · all time
Who traded when
BuySaleNancy A. Grygiel5 sales
Khosla Rachna4 sales
Derek Miller3 sales
Gordon Murdo2 sales
Matthew C. Busch2 sales
Analyst consensus: bullish or bearish?
Analysts rate Amgen Inc Hold (neutral), based on 29 analysts. Average price target: US$394.98.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,281 of 24,148 companies
61.5
score / 100
Value47
Quality76
FCF yld3.5%
Earn yld3.3%
EV/EBITDA17.1x
ROE91%
Gross mgn67%
Net mgn21%
Debt/EBITDA3.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$432.49
Analyst consensus
29 analystsHold
US$225.00Target US$394.98(-9%)US$500.00
Income statement
RevenueUS$36.8B
Gross profitUS$24.7B67% margin
EBITDAUS$16.9B46% margin
Net incomeUS$7.7B23.0% margin
Valuation
PER (trailing)26.9x
PER (forward)17.7x
P/Book20.0x
Beta0.41
Balance sheet & cash
Market capUS$233.8B
Total debtUS$54.6B
Free Cash FlowUS$8.1B
Debt / Equity490%
Profitability & ownership
ROE91.5%
ROA8.7%
% insiders0.2%
% institutions85.1%
Last declaration on 13 August 2026
Declarations483 total
1,252 shares@ US$412.75960.0002% mcap10.3% of flowCommonSEC144:0001959173-26-005970
1,252 shares@ US$416.42560.0002% mcap10.3% of flowCommon StockSEC:0000318154-26-000137:2
2,000 shares@ US$412.5670.0004% mcap16.4% of flowCommon StockSEC:0000318154-26-000137:0
1,252 shares@ US$162.600.0001% mcap4.0% of flowCommon StockSEC:0000318154-26-000137:1
730 shares0Common StockSEC:0000318154-26-000135:0
2,000 shares@ US$414.210.0004% mcap16.4% of flowCommonSEC144:0001959173-26-005894
63.876 shares0Common StockSEC:0000318154-26-000131:0
103.419 shares0Common StockSEC:0000318154-26-000132:0
85.169 shares0Common StockSEC:0000318154-26-000133:0
1,970 shares@ US$402.16010.0003% mcap8.9% of flowCommon StockSEC:0000318154-26-000129:1
1,000 shares@ US$402.16010.0002% mcap4.5% of flowCommon StockSEC:0000318154-26-000129:3
1,970 shares@ US$177.460.0002% mcap3.9% of flowCommon StockSEC:0000318154-26-000129:0
1,000 shares@ US$177.310.0001% mcap2.0% of flowCommon StockSEC:0000318154-26-000129:2
2,069 shares@ US$162.600.0001% mcap8.2% of flowCommon StockSEC:0000318154-26-000130:0
2,069 shares@ US$402.54440.0004% mcap20.4% of flowCommon StockSEC:0000318154-26-000130:1
1,821 shares@ US$402.54440.0003% mcap18.0% of flowCommon StockSEC:0000318154-26-000130:3
1,821 shares@ US$177.460.0001% mcap7.9% of flowCommon StockSEC:0000318154-26-000130:2
2,670 shares@ US$447.16850.0005% mcap13.4% of flowCommonSEC144:0001974078-26-000295
3,890 shares@ US$404.850.0007% mcap100.0% of flowCommonSEC144:0001958244-26-000492
665 shares0Common StockSEC:0000318154-26-000098:0
665 shares0Common StockSEC:0000318154-26-000099:0
665 shares0Common StockSEC:0000318154-26-000100:0
665 shares0Common StockSEC:0000318154-26-000101:0
665 shares0Common StockSEC:0000318154-26-000102:0
665 shares0Common StockSEC:0000318154-26-000103:0
25 of 483 declarations
About Amgen Inc
Amgen Inc. is a major U.S. biopharmaceutical company listed on the NASDAQ under ticker AMGN, with headquarters in Thousand Oaks, California, United States. Founded in 1980, Amgen is widely regarded as one of the pioneers of modern biotechnology and played an important role in helping establish the biotech industry from its earliest years. Today, the company is one of the leading independent biotechnology firms globally, with a business model focused on discovering, developing, manufacturing, and commercializing innovative medicines for serious and chronic diseases. ([amgen.com](https://www.amgen.com/about?utm_source=openai))
Amgen’s core business is organized around four therapeutic areas: general medicine, rare diseases, inflammation, and oncology. Its portfolio includes several well-established brands that matter to institutional investors, including Repatha for cholesterol lowering and cardiovascular risk reduction, Enbrel in inflammatory disease, Prolia and Xgeva in bone health, Otezla in psoriasis and inflammatory conditions, and Tezspire in severe asthma. Following the Horizon Therapeutics acquisition, Amgen strengthened its exposure to rare disease and specialized immunology assets such as Tepezza, Krystexxa, and Uplizna. ([amgen.com](https://www.amgen.com/products?utm_source=openai))
Read moreShow less
From a competitive standpoint, Amgen combines scale, a diversified commercial base, and a sizeable portfolio of mature products with an active pipeline. Management emphasizes the company’s use of biology, human genetic data, and technology to accelerate innovation and improve manufacturing efficiency. Geographically, Amgen has a strong U.S. base but also generates sales across multiple international regions, giving it broad global reach while remaining firmly anchored in the United States market. ([amgen.com](https://www.amgen.com/about?utm_source=openai))
Recent developments are strategically important. In 2025 and 2026, Amgen reported positive phase 3 data for Repatha in primary cardiovascular prevention, encouraging clinical updates for Tezspire and Uplizna, and a new $300 million investment in its U.S. manufacturing network. The company also announced a $900 million expansion in Ohio and a more than $600 million science-and-innovation center at its Thousand Oaks headquarters. These actions reinforce Amgen’s current strategy: expand its industrial footprint, support supply reliability, and continue advancing high-value therapies across key disease areas. ([amgen.com](https://www.amgen.com/newsroom/press-releases/2025/10/landmark-phase-3-trial-vesaliuscv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12000-patients?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
